Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C a retrospective multicenter analysis of 652 patients
A retrospective multicenter analysis of 652 patients with chronic hepatitis C who have been treated with interferon (IFN) was performed to assess the effects of IFN on the clinical course and development of HCC. During a mean follow-up of 54.8 months, hepatocellular carcinoma (HCC) developed in 7.0%...
Gespeichert in:
| Veröffentlicht in: | Digestive diseases and sciences 2002, Vol.47 (1), p.170-176 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 176 |
|---|---|
| container_issue | 1 |
| container_start_page | 170 |
| container_title | Digestive diseases and sciences |
| container_volume | 47 |
| creator | TAKIMOTO, Mitsuhiro OHKOSHI, Shogo HARA, Hidenori OHTA, Hironobu SOGA, Kenji WATANABE, Toshiaki KAMIMURA, Tomoteru ICHIDA, Takafumi TAKEDA, Yasuo NOMOTO, Minoru ASAKURA, Hitoshi NAITO, Akira MORI, Shigeki HATA, Kojiro IGARASHI, Kentaro |
| description | A retrospective multicenter analysis of 652 patients with chronic hepatitis C who have been treated with interferon (IFN) was performed to assess the effects of IFN on the clinical course and development of HCC. During a mean follow-up of 54.8 months, hepatocellular carcinoma (HCC) developed in 7.0% of the patients. The rate was significantly higher in the patients who did not respond to IFN treatment than in those with sustained virological response and those who obtained a normalization of alanine aminotransferase levels despite the presence of HCV RNA (incomplete response) (P < 0.01). Using multivariate Cox's proportional hazard model, alcohol abuse (P < 0.05) and a higher level of fibrosis (P < 0.05) before treatment were the significant background factors associated with HCC development in the patients who did not respond to IFN. Interestingly, a significant increase in the rate of HCC development occurred in patients who had a histological finding of progressive fibrosis (F3). In addition, patients with low histological staging scores were likely to have an incomplete response, even if a sustained virological response was not obtained. IFN produced an improvement in histological activity and fibrosis stage in the second biopsy specimens irrespective of the clinical outcome when compared against untreated subjects. |
| doi_str_mv | 10.1023/A:1013244326874 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_71446412</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>390323501</sourcerecordid><originalsourceid>FETCH-LOGICAL-c310t-73712be20a021aad7d24e9c4265cb44b964fa6d7e5f8e218519d5345d66e8cb73</originalsourceid><addsrcrecordid>eNpd0U2LFDEQBuAgiju7evYmQdDbaCqf3d6WQdeFBS96btLp6u1ae9Jjklb2n_nzzLCjgqeE4uF9i4SxFyDegpDq3eV7EKCk1kraxulHbAPGqa00tnnMNgJsvQPYM3ae850QonVgn7IzgEY5J8WG_bqOBdOIaYmc4kQ9lcwPablNmDPV4TLymX5g4iP1acmUuY8DTzisATMvE_JE-duRTXjwZQk-BYrLLUY8Yoq8Tgljjf1JZeJhqlUUHjSVSnbc17xSww8YSu3i-3UuFPC4WW3z8_0xqTZYI_-mPWNPRj9nfH46L9jXjx--7D5tbz5fXe8ub7ZBgShbpxzIHqXwQoL3gxukxjZoaU3ote5bq0dvB4dmbFBCY6AdjNJmsBab0Dt1wd485NZH-b5iLt2ecsB59hGXNXcOtLYaZIWv_oN3y5rq9rmToJXRTWsrenlCa7_HoTsk2vt03_35kApen4DPwc9j8jFQ_ueUts4Jp34Dyp-d8w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>214354896</pqid></control><display><type>article</type><title>Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C a retrospective multicenter analysis of 652 patients</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>TAKIMOTO, Mitsuhiro ; OHKOSHI, Shogo ; HARA, Hidenori ; OHTA, Hironobu ; SOGA, Kenji ; WATANABE, Toshiaki ; KAMIMURA, Tomoteru ; ICHIDA, Takafumi ; TAKEDA, Yasuo ; NOMOTO, Minoru ; ASAKURA, Hitoshi ; NAITO, Akira ; MORI, Shigeki ; HATA, Kojiro ; IGARASHI, Kentaro</creator><creatorcontrib>TAKIMOTO, Mitsuhiro ; OHKOSHI, Shogo ; HARA, Hidenori ; OHTA, Hironobu ; SOGA, Kenji ; WATANABE, Toshiaki ; KAMIMURA, Tomoteru ; ICHIDA, Takafumi ; TAKEDA, Yasuo ; NOMOTO, Minoru ; ASAKURA, Hitoshi ; NAITO, Akira ; MORI, Shigeki ; HATA, Kojiro ; IGARASHI, Kentaro</creatorcontrib><description>A retrospective multicenter analysis of 652 patients with chronic hepatitis C who have been treated with interferon (IFN) was performed to assess the effects of IFN on the clinical course and development of HCC. During a mean follow-up of 54.8 months, hepatocellular carcinoma (HCC) developed in 7.0% of the patients. The rate was significantly higher in the patients who did not respond to IFN treatment than in those with sustained virological response and those who obtained a normalization of alanine aminotransferase levels despite the presence of HCV RNA (incomplete response) (P < 0.01). Using multivariate Cox's proportional hazard model, alcohol abuse (P < 0.05) and a higher level of fibrosis (P < 0.05) before treatment were the significant background factors associated with HCC development in the patients who did not respond to IFN. Interestingly, a significant increase in the rate of HCC development occurred in patients who had a histological finding of progressive fibrosis (F3). In addition, patients with low histological staging scores were likely to have an incomplete response, even if a sustained virological response was not obtained. IFN produced an improvement in histological activity and fibrosis stage in the second biopsy specimens irrespective of the clinical outcome when compared against untreated subjects.</description><identifier>ISSN: 0163-2116</identifier><identifier>EISSN: 1573-2568</identifier><identifier>DOI: 10.1023/A:1013244326874</identifier><identifier>PMID: 11837720</identifier><identifier>CODEN: DDSCDJ</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Alanine Transaminase - blood ; Biological and medical sciences ; Carcinoma, Hepatocellular - prevention & control ; Female ; Hepatitis C, Chronic - therapy ; Humans ; Immunomodulators ; Interferon-alpha - therapeutic use ; Interferon-beta - therapeutic use ; Liver Cirrhosis - therapy ; Liver Neoplasms - prevention & control ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Retrospective Studies</subject><ispartof>Digestive diseases and sciences, 2002, Vol.47 (1), p.170-176</ispartof><rights>2002 INIST-CNRS</rights><rights>Copyright Kluwer Academic Publishers Jan 2002</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c310t-73712be20a021aad7d24e9c4265cb44b964fa6d7e5f8e218519d5345d66e8cb73</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4021,27921,27922,27923</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13467707$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11837720$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>TAKIMOTO, Mitsuhiro</creatorcontrib><creatorcontrib>OHKOSHI, Shogo</creatorcontrib><creatorcontrib>HARA, Hidenori</creatorcontrib><creatorcontrib>OHTA, Hironobu</creatorcontrib><creatorcontrib>SOGA, Kenji</creatorcontrib><creatorcontrib>WATANABE, Toshiaki</creatorcontrib><creatorcontrib>KAMIMURA, Tomoteru</creatorcontrib><creatorcontrib>ICHIDA, Takafumi</creatorcontrib><creatorcontrib>TAKEDA, Yasuo</creatorcontrib><creatorcontrib>NOMOTO, Minoru</creatorcontrib><creatorcontrib>ASAKURA, Hitoshi</creatorcontrib><creatorcontrib>NAITO, Akira</creatorcontrib><creatorcontrib>MORI, Shigeki</creatorcontrib><creatorcontrib>HATA, Kojiro</creatorcontrib><creatorcontrib>IGARASHI, Kentaro</creatorcontrib><title>Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C a retrospective multicenter analysis of 652 patients</title><title>Digestive diseases and sciences</title><addtitle>Dig Dis Sci</addtitle><description>A retrospective multicenter analysis of 652 patients with chronic hepatitis C who have been treated with interferon (IFN) was performed to assess the effects of IFN on the clinical course and development of HCC. During a mean follow-up of 54.8 months, hepatocellular carcinoma (HCC) developed in 7.0% of the patients. The rate was significantly higher in the patients who did not respond to IFN treatment than in those with sustained virological response and those who obtained a normalization of alanine aminotransferase levels despite the presence of HCV RNA (incomplete response) (P < 0.01). Using multivariate Cox's proportional hazard model, alcohol abuse (P < 0.05) and a higher level of fibrosis (P < 0.05) before treatment were the significant background factors associated with HCC development in the patients who did not respond to IFN. Interestingly, a significant increase in the rate of HCC development occurred in patients who had a histological finding of progressive fibrosis (F3). In addition, patients with low histological staging scores were likely to have an incomplete response, even if a sustained virological response was not obtained. IFN produced an improvement in histological activity and fibrosis stage in the second biopsy specimens irrespective of the clinical outcome when compared against untreated subjects.</description><subject>Alanine Transaminase - blood</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Hepatocellular - prevention & control</subject><subject>Female</subject><subject>Hepatitis C, Chronic - therapy</subject><subject>Humans</subject><subject>Immunomodulators</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Interferon-beta - therapeutic use</subject><subject>Liver Cirrhosis - therapy</subject><subject>Liver Neoplasms - prevention & control</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Retrospective Studies</subject><issn>0163-2116</issn><issn>1573-2568</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpd0U2LFDEQBuAgiju7evYmQdDbaCqf3d6WQdeFBS96btLp6u1ae9Jjklb2n_nzzLCjgqeE4uF9i4SxFyDegpDq3eV7EKCk1kraxulHbAPGqa00tnnMNgJsvQPYM3ae850QonVgn7IzgEY5J8WG_bqOBdOIaYmc4kQ9lcwPablNmDPV4TLymX5g4iP1acmUuY8DTzisATMvE_JE-duRTXjwZQk-BYrLLUY8Yoq8Tgljjf1JZeJhqlUUHjSVSnbc17xSww8YSu3i-3UuFPC4WW3z8_0xqTZYI_-mPWNPRj9nfH46L9jXjx--7D5tbz5fXe8ub7ZBgShbpxzIHqXwQoL3gxukxjZoaU3ote5bq0dvB4dmbFBCY6AdjNJmsBab0Dt1wd485NZH-b5iLt2ecsB59hGXNXcOtLYaZIWv_oN3y5rq9rmToJXRTWsrenlCa7_HoTsk2vt03_35kApen4DPwc9j8jFQ_ueUts4Jp34Dyp-d8w</recordid><startdate>2002</startdate><enddate>2002</enddate><creator>TAKIMOTO, Mitsuhiro</creator><creator>OHKOSHI, Shogo</creator><creator>HARA, Hidenori</creator><creator>OHTA, Hironobu</creator><creator>SOGA, Kenji</creator><creator>WATANABE, Toshiaki</creator><creator>KAMIMURA, Tomoteru</creator><creator>ICHIDA, Takafumi</creator><creator>TAKEDA, Yasuo</creator><creator>NOMOTO, Minoru</creator><creator>ASAKURA, Hitoshi</creator><creator>NAITO, Akira</creator><creator>MORI, Shigeki</creator><creator>HATA, Kojiro</creator><creator>IGARASHI, Kentaro</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>2002</creationdate><title>Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C a retrospective multicenter analysis of 652 patients</title><author>TAKIMOTO, Mitsuhiro ; OHKOSHI, Shogo ; HARA, Hidenori ; OHTA, Hironobu ; SOGA, Kenji ; WATANABE, Toshiaki ; KAMIMURA, Tomoteru ; ICHIDA, Takafumi ; TAKEDA, Yasuo ; NOMOTO, Minoru ; ASAKURA, Hitoshi ; NAITO, Akira ; MORI, Shigeki ; HATA, Kojiro ; IGARASHI, Kentaro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c310t-73712be20a021aad7d24e9c4265cb44b964fa6d7e5f8e218519d5345d66e8cb73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Alanine Transaminase - blood</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Hepatocellular - prevention & control</topic><topic>Female</topic><topic>Hepatitis C, Chronic - therapy</topic><topic>Humans</topic><topic>Immunomodulators</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Interferon-beta - therapeutic use</topic><topic>Liver Cirrhosis - therapy</topic><topic>Liver Neoplasms - prevention & control</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>TAKIMOTO, Mitsuhiro</creatorcontrib><creatorcontrib>OHKOSHI, Shogo</creatorcontrib><creatorcontrib>HARA, Hidenori</creatorcontrib><creatorcontrib>OHTA, Hironobu</creatorcontrib><creatorcontrib>SOGA, Kenji</creatorcontrib><creatorcontrib>WATANABE, Toshiaki</creatorcontrib><creatorcontrib>KAMIMURA, Tomoteru</creatorcontrib><creatorcontrib>ICHIDA, Takafumi</creatorcontrib><creatorcontrib>TAKEDA, Yasuo</creatorcontrib><creatorcontrib>NOMOTO, Minoru</creatorcontrib><creatorcontrib>ASAKURA, Hitoshi</creatorcontrib><creatorcontrib>NAITO, Akira</creatorcontrib><creatorcontrib>MORI, Shigeki</creatorcontrib><creatorcontrib>HATA, Kojiro</creatorcontrib><creatorcontrib>IGARASHI, Kentaro</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Digestive diseases and sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>TAKIMOTO, Mitsuhiro</au><au>OHKOSHI, Shogo</au><au>HARA, Hidenori</au><au>OHTA, Hironobu</au><au>SOGA, Kenji</au><au>WATANABE, Toshiaki</au><au>KAMIMURA, Tomoteru</au><au>ICHIDA, Takafumi</au><au>TAKEDA, Yasuo</au><au>NOMOTO, Minoru</au><au>ASAKURA, Hitoshi</au><au>NAITO, Akira</au><au>MORI, Shigeki</au><au>HATA, Kojiro</au><au>IGARASHI, Kentaro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C a retrospective multicenter analysis of 652 patients</atitle><jtitle>Digestive diseases and sciences</jtitle><addtitle>Dig Dis Sci</addtitle><date>2002</date><risdate>2002</risdate><volume>47</volume><issue>1</issue><spage>170</spage><epage>176</epage><pages>170-176</pages><issn>0163-2116</issn><eissn>1573-2568</eissn><coden>DDSCDJ</coden><abstract>A retrospective multicenter analysis of 652 patients with chronic hepatitis C who have been treated with interferon (IFN) was performed to assess the effects of IFN on the clinical course and development of HCC. During a mean follow-up of 54.8 months, hepatocellular carcinoma (HCC) developed in 7.0% of the patients. The rate was significantly higher in the patients who did not respond to IFN treatment than in those with sustained virological response and those who obtained a normalization of alanine aminotransferase levels despite the presence of HCV RNA (incomplete response) (P < 0.01). Using multivariate Cox's proportional hazard model, alcohol abuse (P < 0.05) and a higher level of fibrosis (P < 0.05) before treatment were the significant background factors associated with HCC development in the patients who did not respond to IFN. Interestingly, a significant increase in the rate of HCC development occurred in patients who had a histological finding of progressive fibrosis (F3). In addition, patients with low histological staging scores were likely to have an incomplete response, even if a sustained virological response was not obtained. IFN produced an improvement in histological activity and fibrosis stage in the second biopsy specimens irrespective of the clinical outcome when compared against untreated subjects.</abstract><cop>Heidelberg</cop><pub>Springer</pub><pmid>11837720</pmid><doi>10.1023/A:1013244326874</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0163-2116 |
| ispartof | Digestive diseases and sciences, 2002, Vol.47 (1), p.170-176 |
| issn | 0163-2116 1573-2568 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71446412 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Alanine Transaminase - blood Biological and medical sciences Carcinoma, Hepatocellular - prevention & control Female Hepatitis C, Chronic - therapy Humans Immunomodulators Interferon-alpha - therapeutic use Interferon-beta - therapeutic use Liver Cirrhosis - therapy Liver Neoplasms - prevention & control Male Medical sciences Middle Aged Pharmacology. Drug treatments Retrospective Studies |
| title | Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C a retrospective multicenter analysis of 652 patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T02%3A55%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interferon%20inhibits%20progression%20of%20liver%20fibrosis%20and%20reduces%20the%20risk%20of%20hepatocarcinogenesis%20in%20patients%20with%20chronic%20hepatitis%20C%20a%20retrospective%20multicenter%20analysis%20of%20652%20patients&rft.jtitle=Digestive%20diseases%20and%20sciences&rft.au=TAKIMOTO,%20Mitsuhiro&rft.date=2002&rft.volume=47&rft.issue=1&rft.spage=170&rft.epage=176&rft.pages=170-176&rft.issn=0163-2116&rft.eissn=1573-2568&rft.coden=DDSCDJ&rft_id=info:doi/10.1023/A:1013244326874&rft_dat=%3Cproquest_pubme%3E390323501%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=214354896&rft_id=info:pmid/11837720&rfr_iscdi=true |